Sutro Biopharma, Inc.
NASDAQ:STROBiotechnology
Healthcare
$8.72 +1.13%
+$0.32 today
- Market cap
- $144.76M
- Beta
- 1.55
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$1,174.12
52W Low $6.70High $43.85
Volume 0.24M
Average 0.28M
Income Statement
Follow revenue through to earnings.
Revenue
$102.48M
FY 2025 · Annual
+65.2% YoYOperating Income
-$104.95M
FY 2025 · Annual
Net Income
-$191.09M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 61.88M | 67.77M | 153.73M | 62.04M | 102.48M |
| Cost of Revenue | 9.77M | 8.29M | 6.82M | 7.22M | 7.32M |
| Gross Profit | 52.11M | 59.48M | 146.92M | 54.83M | 95.16M |
| Gross Margin | 84.2% | 87.8% | 95.6% | 88.4% | 92.9% |
| Research & Development | 104.4M | 137.17M | 180.43M | 252.04M | 166.42M |
| Selling, General & Admin | 56M | 59.54M | 62.58M | 48.45M | 41.02M |
| Operating Expenses | 150.63M | 188.43M | 236.19M | 293.28M | 200.11M |
| Depreciation & Amortization | 4.84M | 8.29M | 6.82M | 7.22M | 7.32M |
| EBITDA | (97.56M) | (105.07M) | (67.92M) | (180.45M) | (145.65M) |
| EBITDA Margin | -157.7% | -155.0% | -44.2% | -290.9% | -142.1% |
| Operating Income | (98.52M) | (128.94M) | (89.28M) | (238.45M) | (104.95M) |
| Operating Margin | -159.2% | -190.3% | -58.1% | -384.3% | -102.4% |
| Interest Income | 577K | 3.46M | 14.51M | 44.43M | 9.25M |
| Interest Expense | 3.14M | 3.35M | 23.75M | 31.07M | 38.21M |
| Other Income / Expenses | (7.01M) | 12.24M | 677K | 13.36M | (86.23M) |
| Income Before Tax | (105.54M) | (116.7M) | (88.6M) | (225.1M) | (191.18M) |
| Pre-Tax Margin | -170.6% | -172.2% | -57.6% | -362.8% | -186.5% |
| Income Tax Expense | 0 | 2.5M | 18.19M | 2.36M | (93K) |
| Net Income | (105.54M) | (119.2M) | (106.79M) | (227.46M) | (191.09M) |
| Net Margin | -170.6% | -175.9% | -69.5% | -366.6% | -186.5% |
| EPS (Basic) | (22.90) | (23.50) | (17.80) | (29.60) | (22.49) |
| EPS (Diluted) | (22.90) | (23.50) | (17.80) | (29.60) | (22.49) |
| 4.61M | 5.07M | 6.02M | 7.68M | 8.5M | |
| 4.61M | 5.07M | 6.02M | 7.68M | 8.5M |
STRO Earnings Waterfall · TTM
NASDAQ:STRO · Revenue to Net Income
Key Ratios
EPS$-307.72
Gross Margin97.8%
Net Margin-317.8%
P/E Ratio-0.5
P/S Ratio4.3
Analysis
$99.6M of revenue converted into -$153.6M of net income for the selected period. Gross margin is 97.8% and net margin is -317.8%, showing how much revenue survives after costs and taxes. EPS is $-307.72, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| SC 13G | SC 13G filing | Nov 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 22, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 |
How much revenue does STRO generate?
Sutro Biopharma, Inc. (STRO) reported $102.48M of revenue in fiscal 2025.
Is STRO profitable?
Sutro Biopharma, Inc. (STRO) reported -$191.09M of net income, with a net margin of -186.5%.
Continue the stock analysis
Jump to another research area for this company.